DYN saw its Momentum Indicator move below the 0 level on October 12, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In 69 of the 79 cases, the stock moved further down in the following days. The odds of a decline are at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DYN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for DYN entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for DYN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for DYN just turned positive on October 01, 2026. Looking at past instances where DYN's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
Following a +4.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where DYN advanced for three days, in 240 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
DYN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.790) is normal, around the industry mean (2.835). P/E Ratio (-4.371) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. DYN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DYN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
XNCR moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend. In 28 of 32 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XNCR as a result. In 61 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The 10-day moving average for XNCR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for XNCR entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +2.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where XNCR advanced for three days, in 189 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
XNCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.376) is normal, around the industry mean (2.835). P/E Ratio (-10.579) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.740) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (16.949) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DYN | XNCR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 48 Fair valued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 82 | 36 | |
P/E GROWTH RATING 1..100 | 26 | 29 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XNCR's Valuation (20) in the Biotechnology industry is in the same range as DYN (48) in the Electric Utilities industry. This means that XNCR’s stock grew similarly to DYN’s over the last 12 months.
XNCR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DYN (100) in the Electric Utilities industry. This means that XNCR’s stock grew similarly to DYN’s over the last 12 months.
XNCR's SMR Rating (97) in the Biotechnology industry is in the same range as DYN (98) in the Electric Utilities industry. This means that XNCR’s stock grew similarly to DYN’s over the last 12 months.
XNCR's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for DYN (82) in the Electric Utilities industry. This means that XNCR’s stock grew somewhat faster than DYN’s over the last 12 months.
DYN's P/E Growth Rating (26) in the Electric Utilities industry is in the same range as XNCR (29) in the Biotechnology industry. This means that DYN’s stock grew similarly to XNCR’s over the last 12 months.
| DYN | XNCR | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 85% | N/A |
| Stochastic ODDS (%) | 4 days ago 76% | 4 days ago 63% |
| Momentum ODDS (%) | 4 days ago 87% | 4 days ago 79% |
| MACD ODDS (%) | 4 days ago 83% | N/A |
| TrendWeek ODDS (%) | 4 days ago 85% | 4 days ago 84% |
| TrendMonth ODDS (%) | 4 days ago 87% | 4 days ago 83% |
| Advances ODDS (%) | 11 days ago 84% | 8 days ago 74% |
| Declines ODDS (%) | 6 days ago 85% | 6 days ago 82% |
| BollingerBands ODDS (%) | 4 days ago 76% | 4 days ago 71% |
| Aroon ODDS (%) | 4 days ago 84% | 4 days ago 84% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DYN’s FA Score shows that 1 FA rating(s) are green while XNCR’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DYN’s TA Score shows that 5 TA indicator(s) are bullish while XNCR’s TA Score has 3 bullish TA indicator(s).
DYN (@Biotechnology) experienced а -14.36% price change this week, while XNCR (@Biotechnology) price change was -7.23% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.77%. For the same industry, the average monthly price growth was -18.56%, and the average quarterly price growth was -19.45%.
DYN is expected to report earnings on Oct 29, 2026.
XNCR is expected to report earnings on Nov 09, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SPXS | 24.82 | 0.82 | +3.42% |
| Direxion Daily S&P 500 Bear 3X ETF (SPXS) | |||
| SSFI | 20.48 | 0.11 | +0.54% |
| Day Hagan / Ned Davis Research Smart Sector Fixed Income ETF (SSFI) | |||
| HMAY | 25.44 | -0.03 | -0.11% |
| Corgi U.S. Equities 100% Structured Buffer ETF (HMAY) | |||
| CHIQ | 16.20 | -0.06 | -0.36% |
| Global X MSCI China Consumer Discretionary ETF (CHIQ) | |||
| FMAY | 57.41 | -0.42 | -0.73% |
| FT Vest U.S. Equity Buffer Fund - May (FMAY) | |||
A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with KURA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then KURA could also see price increases.
| Ticker / NAME | Correlation To XNCR | 1D Price Change % | ||
|---|---|---|---|---|
| XNCR | 100% | -4.79% | ||
| KURA - XNCR | 53% Loosely correlated | -6.39% | ||
| VCYT - XNCR | 52% Loosely correlated | -2.86% | ||
| RCUS - XNCR | 48% Loosely correlated | -3.07% | ||
| VIR - XNCR | 47% Loosely correlated | -4.87% | ||
| DYN - XNCR | 45% Loosely correlated | -6.80% | ||
More | ||||